Despite evidence suggesting a familial clustering of Hodgkin's lymphoma (HL), [1] [2] [3] [4] [5] [6] there is no clear understanding on the relative contribution of genes and shared environmental factors, including childhood infections, 7, 8 to familial risk. The rarity of familial HL has hampered a detailed analysis of the familial clustering and it has probably contributed to the variation even in recent risk estimates for first-degree relatives, such as 4.9 from Utah 5 and 3.27 from Iceland. 4 The Swedish Family-Cancer Database is the largest populationbased data set with familial information, covering over 10.5 million individuals. We assess here the familial risks of HL in offspring with a parent or a sibling affected with HL, according to age and sex. This will provide a reliable quantification of the familial risk and suggest plausible modes of inheritance. The Swedish Family-Cancer Database includes nearly all individuals born from 1932 onward (second generation) with their biological parents (first generation). This Database was linked to the Swedish Cancer Registry for malignancies diagnosed between 1958 and 2002. Socio-demographic information was obtained by linkage to the nationwide censuses. Standardized incidence ratios (SIRs) were used to estimate familial relative risks computed as the ratio of the number of observed cases to the number of expected cases. Confidence intervals were calculated under the assumption of a Poisson distribution. In order to make a proper comparison between risks in individuals with a parent or a sibling affected, we limited the parental age to 70 years (same as in offspring). The Database contained 3238 (1907 males, 1331 females) offspring with HL.
The Table 1 shows familial SIRs of HL. The SIR for offspring with a parent affected was 3.05, higher in males compared to females. The highest risks for individuals with an affected parent were found for parental age at diagnosis o40 years (SIR ¼ 6.46). The risk of HL for an affected sibling was 5.56. The highest risks were found for brother-brother (SIR ¼ 8.00) and sister-sister (SIR ¼ 11.75) pairs. Even though the one male twin pair was excluded, the risk remained at 6.40 (see Table 1 footnote).
We confirmed and further quantified the strong familial clustering of HL, [1] [2] [3] [4] [5] [6] being among the highest for any malignancy in the Database; the sibling risk of over 5 ranks second after testicular cancer. 9 The higher risks for siblings compared to parent-offspring pairs suggest a recessive component or childhood shared effects. This is the first study providing familial risks by sex of the proband and the relative. The remarkable high risks found in same-sex siblings is not readily explainable, and it may be due to the small sample size or to yet unrecognized environmental or genetic factors. The familial risks in strata of age suggest higher risks at a relatively young age.
The strength of this study was the availability of populationbased data with registered-based family relations, excluding any type of recall and misclassification bias. Among the limitations, we could not distinguish between heritable genetic and environmental factors as causes of familial aggregation. Nevertheless, the high familial risks observed The Database included an affected male twin pair. When we excluded these two siblings the risk for brother-brother pairs was 6.40 (95% CI, 1.66-15.38).
Letters to the Editor suggest underlying genetic susceptibility and call for concerted collections of biological material from familial cases to enable genetic studies.
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2 V617F positive, del (5) Lenalidomide (Revlimid; Celgene Co.) has ameliorated cytopenias and induced cytogenetic responses in patients with myelodysplastic syndrome (MDS), especially those with del(5)(q13q33). 1 Additionally, we have similarly reported cytogenetic and hematologic response in a patient with myelofibrosis with myeloid metaplasia with del (5)(q13q33) whom also had the JAK2 V617F . 2 However, no data exist regarding the efficacy of lenalidomide in patients with del(5)(q13q33) who have progressed to acute myeloid leukemia (AML). An 82-year-old woman presented to our institution with a several year history of untreated MDS associated with mild anemia, thrombocytosis and isolated del(5)(q13q33). Subsequently, in response to worsening cytopenias (hemoglobin 9.9 g/dl, leukocytes 1.5 Â 10 9 /l (neutrophils 0.45 Â 10 9 /l)), and peripheral circulating blasts (2%), a bone marrow was obtained. The marrow demonstrated minimally differentiated AML (AML-M0) Figure 1 Effects of lenalidomide monotherapy on an 82-year-old woman with a MDS with both the JAK2 V617F mutation and the del(5)(q13q33). (a) Bone marrow aspirate (hematoxylin and eosin; Â 1000 oil lens -light microscopy) at the time of diagnosis of leukemic transformation with 34% myeloblasts. (b) Repeat bone marrow aspirate (same conditions) after 3 months of lenalidomide with 5% myeloblasts, improved granulocytic maturation and normal peripheral blood counts.
